New treatment for severe lung disease
A US company has entered the Danish market with a treatment option for patients with a lifethreatening lung disease. According to EMA, there are no other treatment options on the Danish market.
af LEONORA BECK
The US-based biotech company Intermune is now offering a treatment of the lung disease idiopathic pulmonary fibrosis (IPF) to Danish patients.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
